REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic...
Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient careCONSHOHOCKEN, Pa., June 06, 2022...
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or...
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data...
MINNEAPOLIS, June 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on...
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing...
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential...
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated...
- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that...
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology...
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due...
The Lachine Hospital Foundation and the MUHC Foundation joined forces to create a tropical paradise for the first Lachine gala...
Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging preclinical data presented at the...
-- Presentation at ASCO features updated results from Phase 2 ACCURACY study -- -- AL101 demonstrated anti-tumor activity by achieving...
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused...
SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a...
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrate unique biology, continued tolerability, and dose-dependent pharmacodynamic...
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...